S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NASDAQ:RCKT

Rocket Pharmaceuticals Stock Forecast, Price & News

$53.59
-3.35 (-5.88 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$53.39
Now: $53.59
$57.85
50-Day Range
$32.03
MA: $55.34
$60.16
52-Week Range
$9.01
Now: $53.59
$63.99
Volume312,170 shs
Average Volume485,494 shs
Market Capitalization$2.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Rocket Pharmaceuticals logo

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

339th out of 1,925 stocks

Pharmaceutical Preparations Industry

177th out of 773 stocks

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100
Employees84
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.10 per share

Profitability

Net Income$-77,270,000.00

Miscellaneous

Market Cap$2.96 billion
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable
$53.59
-3.35 (-5.88 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

How has Rocket Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCKT stock has increased by 235.1% and is now trading at $53.59.
View which stocks have been most impacted by COVID-19
.

Is Rocket Pharmaceuticals a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rocket Pharmaceuticals stock.
View analyst ratings for Rocket Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Rocket Pharmaceuticals?

Wall Street analysts have given Rocket Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rocket Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Rocket Pharmaceuticals
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its earnings results on Wednesday, November, 4th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.08.
View Rocket Pharmaceuticals' earnings history
.

What price target have analysts set for RCKT?

12 Wall Street analysts have issued 1-year price targets for Rocket Pharmaceuticals' stock. Their forecasts range from $33.00 to $100.00. On average, they expect Rocket Pharmaceuticals' share price to reach $55.75 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price.
View analysts' price targets for Rocket Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Rocket Pharmaceuticals' key competitors?

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:
  • Mr. Gaurav Shah, CEO, Pres & Director (Age 45, Pay $840.34k)
  • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO, Exec. VP & Head of Devel. (Age 41, Pay $683.91k)
  • Mr. John C. Militello, VP of Fin., Sr. Controller and Principal Financial & Accounting Officer (Age 47)
  • Dr. Claudine Prowse Ph.D., Sr. VP of Strategy and Head of Investor Relations & Corp. Devel.
  • Ms. Sara Turken, Sr. Director of Legal & Compliance and Corp. Sec.
  • Mr. Jonathan Schwartz, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 56)
  • Dr. Gayatri R. Rao J.D., M.D., Global Program Head of FA, LAD-I & PKD Programs and VP
  • Mr. Raj Prabhakar, Sr. VP & Chief Bus. Officer
  • Mr. Jose Trevejo M.D., Ph.D., Chief Devel. Officer of AAV & Sr. VP

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.23%), Nisa Investment Advisors LLC (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Rocket Pharmaceuticals stock include Gaurav Shah, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends for Rocket Pharmaceuticals
.

Which institutional investors are selling Rocket Pharmaceuticals stock?

RCKT stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Rocket Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Rocket Pharmaceuticals stock?

RCKT stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., and Nisa Investment Advisors LLC. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $53.59.

How big of a company is Rocket Pharmaceuticals?

Rocket Pharmaceuticals has a market capitalization of $2.96 billion. The biotechnology company earns $-77,270,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Rocket Pharmaceuticals employs 84 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.